uploads///Chart  Cardio

Eli Lilly’s Cialis and Other Cardiovascular Products in 3Q17

By

Nov. 30 2017, Updated 9:01 a.m. ET

Cardiovascular franchise

Eli Lilly’s (LLY) cardiovascular franchise includes the drugs Cialis and Effient. Cialis is a blockbuster drug with annual sales of over $2.0 billion worldwide, but for 3Q17, both drugs reported lower sales.

Article continues below advertisement

Cialis

Cialis, which is approved for the treatment of erectile dysfunction and benign prostatic hyperplasia, reported revenues of $564.9 million during 3Q17, representing a 4% YoY (year-over-year) fall, compared with $588.2 million in 3Q16.

US sales for Cialis fell 8% due to lower sales and competition from other products. Outside of US markets, the drug’s sales rose 2% YoY, driven by an increase in demand.

Effient

Effient, an antiplatelet, is approved in combination with aspirin for preventing blood clots in arteries and stents and helps reduce the chances of heart problems. Effient reported revenues of $55.9 million during 3Q17, representing a 56% YoY fall in revenues, compared with $127.7 million in 3Q16.

Notably, the Vanguard Health Care ETF (VHT) has 40.0% of its total portfolio in pharmaceutical companies. VHT has 2.3% in Eli Lilly (LLY), 4.2% in Merck (MRK), 5.8% in Pfizer (PFE), 10.4% in Johnson & Johnson (JNJ), and 2.7% in Gilead Sciences (GILD).

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.